HIV prevention pill advised for high-risk groups
WASHINGTON >> Doctors should offer a daily HIV prevention pill to healthy people who are at high risk of getting infected with the virus, an influential health care panel recommended last month.
The new guidelines aim to help cut the nearly 40,000 new HIV infections in the U.S. each year.
Screening people for the HIV virus also is critical. The U.S. Preventive Services Task Force reiterated its long-standing advice that everyone ages 15 to 65 — and anyone who’s pregnant — should be regularly screened, a step to early, lifesaving treatment.
But the latest recommendations went a step further.
Studies show that if people who are still healthy take certain HIV drugs every day, it dramatically reduces their chances of being infected by an HIV-positive sexual partner or from injection drug use.
The approach is called PrEP, or pre-exposure prophylaxis. One brand — a two-medication combo pill named Truvada — so far is approved for preventive use in the U.S.
Don't miss out on what's happening!
Stay in touch with top news, as it happens, conveniently in your email inbox. It's FREE!
The task force said PrEP is only for people at high risk of infection. That includes anyone with an HIV-positive sex partner; who has sex without a condom with someone at high risk of HIV; or who shares needles while injecting drugs.
The recommendations were published in the Journal of the American Medical Association. Other medical groups also urge Truvada for prevention, yet just 17% of people who might benefit were prescribed it last year, according to an accompanying editorial.
Private insurers follow task force recommendations on what preventive care to cover, some at no out-of-pocket cost under rules from former President Barack Obama’s health care law.
“How this recommendation will be implemented is of critical importance because cost is a major barrier,” Drs. Diane Havlir and Susan Buchbinder of the University of California, San Francisco wrote in JAMA Internal Medicine. They weren’t part of the task force.
Without insurance, the average monthly retail cost is nearly $2,000, they noted.
Truvada maker Gilead Sciences Inc. agreed to donate PrEP doses for up to 200,000 uninsured people a year.
Some 1.1 million people are living with HIV in the U.S.
